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Abstract
Due to lower female incidence, estimates of exogenous and endogenous hor-
monal factors in head and neck cancers (HNCs, comprising cancers of the oral 
cavity, oropharynx, hypopharynx, and larynx) among women have been incon-
sistent and unable to account for key HNC risk factors. We pooled data from 
11 studies from Europe, North America, and Japan. Analysis included 1572 
HNC female cases and 4343 controls. Pooled odds ratios (ORs) estimates and 
their 95% confidence intervals (CIs) were calculated using multivariate logistic 
regression models adjusting for tobacco smoking and alcohol drinking. Lower 
risk was observed in women who used hormone replacement therapy (HRT) 
(OR = 0.58; 95% CI: 0.34–0.77). Pregnancy (OR = 0.61; 95% CI: 0.42–0.90) 
and giving birth (OR = 0.59; 95% CI: 0.38–0.90) at <35 years of age were 
inversely associated with HNCs. An inverse association with HNC was observed 
with age at start of HRT use (OR = 0.59; 95% CI: 0.39–0.90) for each additional 
10 years and with duration of use (OR = 0.87; 95% CI: 0.76–0.99 for every 
3 years). Exogenous female hormone use is associated with a nearly twofold 
risk reduction in female HNCs. The lower female HNC incidence may, in part, 
be explained by endogenous and exogenous estrogen exposures.
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Introduction
The male- to- female incidence ratio of head and neck 
cancers (HNCs) of the oral cavity, pharynx, oropharynx, 
hypopharynx, and larynx ranges in the order of 3 to 5 
to 1 [1]. Differences in tobacco smoking, alcohol drink-
ing, and human papilloma virus (HPV) infection do not 
fully explain this sex incidence ratio [2]. Indeed, for 
laryngeal cancer, the male- to- female incidence ratio is the 
highest among non- sex- related neoplasms at 11:1 [1]. HNC 
incidence rates are increasing among females [3, 4] although 
female HNCs are understudied.
The paucity of literature on female HNCs is due to 
low female case numbers available at each individual 
institution, low female HNC incidence, and a lack of 
standardized reproductive or hormone use data collection 
on HNC patients in general [5]. However, estrogen hor-
mone receptors have been shown to be functional [6] in 
HNC cell lines, expressed depending on hormone ligand 
stimulation [7], and, recently, correlated with HNC sur-
vival status [8]. However, the role of hormones in head 
and neck carcinogenesis in a human model remains unclear. 
Epidemiological studies support a favorable role of exog-
enous and endogenous female hormones on HNCs [3, 
5, 9]. However, these studies included <200 cases and 
lacked statistical power to concurrently adjust for both 
tobacco smoking and alcohol drinking confounders.
To clarify the role of hormonal factors in female HNC 
risk, we pooled primary data from 11 HNC case–control 
studies in the International Head and Neck Cancer 
Epidemiology (INHANCE) consortium. This study aimed 
to evaluate the role of female exogenous and endogenous 
hormones on female HNC risk and to determine the 
interaction between female hormones and known risk 
factors with HNC risk.
Methods
Study population
We pooled 1572 female incident HNC cases and 4343 
controls from 11 INHANCE studies (http://www.inhance.
utah.edu/) [10]. Controls were frequency- matched by age, 
sex, and race/ethnicity. Controls obtained via random- 
digit- dialing (Iowa and US multicenter studies) or matched-
 based on residence (Milan (2006–2009)) included 1288 
(25%) participants (Table S1). Case and control participa-
tion rates were greater than 94%, aside from Iowa, US 
multicenter, and Buffalo studies, which had participation 
percent rates over 87%, 75%, and 75%, respectively [11].
Incident HNC cases were defined by the following codes 
of the World Health Organization (WHO) International 
Classification of Disease (ICD- O2 Version 2 [12], ICD- 9 
[13], or ICD- 10 [14]) and included: oral cavity (n = 558), 
(C00.3- C00.9, C02.0- C02.3, C03.0, C03.1, C03.9, C04.0, 
C04.1, C04.8- C05.0, C06.0- C06.2, C06.8, C06.9); oro-
pharynx (n = 339), (C01.9, C02.4, C05.1, C05.2, C09.0, 
C09.1, C09.8, C09.9, C10.0- C10.4, C10.8, C10.9); 
hypopharynx (n = 99) (C12.9, C13.0- 13.2, C13.8, C13.9); 
and larynx (n = 212) (C32.0- C32.3, C32.8, C32.9), as 
well as pharynx not otherwise specified (n = 302) and 
overlapping HN sites (n = 62). Due to the specific HPV- 
driven etiology of oropharyngeal cancers [15], they were 
analyzed separately.
Exposure variables
Data were collected by trained interviewers using struc-
tured questionnaires including menstrual and reproductive 
information, lifelong use of oral contraceptives (OC) and 
hormone replacement therapy (HRT), age at menopause 
and menarche, socio- demographics, and smoking and 
drinking habits. HRT therapy was defined as hormone 
therapy for menopausal symptoms. Written informed 
consent was obtained from all study subjects; each insti-
tutional review board approved investigations.
Questionnaire data were collected from each study to 
assess question wording and data comparability, for data 
harmonization. Reliability for HRT therapy and OC use 
were over 90% and 93%, respectively; for parity and age 
at menopause, 94% and 66%, respectively [16–18]. Study 
subjects had a mean age±standard deviation(SD) of 
59.0 ± 0.17 years, within the upper range of the world 
menopausal age average [19]. Categorical age cut- offs at 
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Table 1. Associations between exogenous and endogenous hormone- related factors with the risk of head and neck cancer and by subsite in 
INHANCE Consortium.
Overall Head and Neck Cancers Oral Cavity Oropharynx
Cases/Controls OR (95% CI) Cases/Controls OR (95% CI) Cases/Controls OR (95% CI)
Exogenous Hormone factors
Ever used HRT1
Never 370/791 1.0 (Ref.) 139/791 1.0 (Ref.) 134/791 1.0 (Ref.)
Ever 626/1,351 0.58 (0.34–0.77) 266/1,351 0.56 (0.32–0.97) 325/1,351 0.49 (0.31–0.77)
Age at first HRT use (years)
Never 122/521 1.0 (ref.) 41/521 1.0 (ref.) 60/521 1.0 (ref.)
<42 51/98 1.59 (0.47–5.35) 21/98 1.05 
(0.10–10.52)
29/98 0.82 (0.08–8.77)
42+ 42/112 0.93 (0.27–3.18) 16/112 0.64 (0.06–7.34) 25/112 2.17 
(0.23–20.19)
Ptrend 0.32 0.34 0.18
Ever used OC2
Never 349/1,373 1.0 (Ref.) 110/1,373 1.0 (Ref.) 150/1,373 1.0 (Ref.)
Ever 88/335 0.59 (0.40–0.86) 31/335 0.64 (0.36–1.17) 33/335 0.55 (0.29–1.07)
Age at first OC use (years)
Never 348/1,372 1.0 (Ref.) 109/1,372 1.0 (Ref.) 150/1,372 1.0 (Ref.)
<31 61/182 0.83 (0.52–1.34) 18/182 0.73 (0.35–1.54) 25/182 0.86 (0.38–1.95)
31+ 30/180 0.37 (0.22–0.63) 14/180 0.55 (0.26–1.18) 10/180 0.31 (0.12–0.79)
Ptrend <0.001 0.12 0.02
Endogenous hormone factors
Ever given birth
No 161/360 1.0 (Ref.) 60/360 1.0 (Ref.) 74/360 1.0 (Ref.)
Yes 400/1612 0.70 (0.52, 0.95) 136/1,612 0.74 (0.47–1.16) 152/1612 0.61 (0.36–1.02)
Age at first pregnancy (years)
Never 119/248 1.0 (Ref.) 47/248 1.0 (Ref.) 54/248 1.0 (Ref.)
<35 555/1980 0.61 (0.42–0.90) 187/1,980 0.55 (0.30–0.98) 261/1,980 0.48 (0.25–0.93)
35+ 17/47 0.82 (0.39–1.71) 5/47 0.65 (0.21–2.08) 8/47 0.43 (0.09–2.13)
Ptrend 0.09 0.11 0.04
Age at first birth (years)
Never 112/232 1.0 (Ref.) 42/232 1.0 (Ref.) 53/232 1.0 (Ref.)
<35 544/1,925 0.59 (0.38–0.90) 182/1,925 0.44 (0.22–0.90) 147/1925 0.48 (0.24–0.95)
35+ 17/47 0.78 (0.37–1.65) 5/47 0.50 (0.14–1.61) 8/47 0.39 (0.08–1.94)
Ptrend 0.03 0.03 0.04
Breastfeeding
No 391/1,197 1.0 (Ref.) 127/1197 1.0 (Ref.) 209/1,197 1.0 (Ref.)
Yes 125/361 0.97 (0.67–1.43) 44/361 1.02 (0.55–1.88) 54/361 0.98 (0.50–1.96)
Menarche age
14 years+ 322/1024 1.0 (Ref.) 110/1024 1.0 (Ref.) 88/1024 1.0 (Ref.)
<14 years 359/1307 0.89 (0.73–1.10) 111/1307 0.81 (0.58–1.12) 95/1307 0.74 (0.50–1.11)
Menopause cause
Pre- and peri 
menopause
115/510 1.0 (Ref.) 41/510 1.0 (Ref.) 56/510 1.0 (Ref.)
Natural 513/1746 1.79 (1.16–2.77) 184/1,746 1.44 (0.72–2.87) 231/1746 1.98 (0.92–4.28)
Surgical 124/423 1.62 (1.02–2.56) 46/423 1.37 (0.67–2.81) 52/423 1.89 (0.92–3.88)
Menopause age
Never 70/416 1.0 (Ref.) 22/416 1.0 (Ref.) 41/416 1.0 (Ref.)
<52 years 476/1494 1.69 (1.06–2.71) 168/1494 0.94 (0.44–2.01) 212/1,494 2.52 (1.02–6.27)
52+ years 172/701 1.54 (0.93–2.57) 63/701 0.86 (0.38–1.92) 78/701 1.88 (0.68–5.24)
Ptrend 0.33 0.56 0.95
Models adjusted for study (and center for multicenter studies), age (<40, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75 +  years), education 
level (≤high school, > high school), amount of alcohol drinking (nondrinker, 0.1–0.9, 1.0–2.9, 3.0–4.9, and 5.0+ drinks/day), body mass index (normal 
weight, underweight, overweight, and obese), and cumulative tobacco smoking (never smoker, smoked 0–10.0, 10.1–20.0, 20.1–30.0, 30.1–40.0, 
40.1–50.0, 50.0+ pack- years).
1HRT, hormone replacement therapy.
2OC, oral contraceptives; OR: Odds ratios.
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menopause and menarche were chosen based on the 
pooled data median. First birth and pregnancy 35+ years 
was chosen based on the clinical definition of advanced 
maternal age, hormonal changes, and cancer risk [20, 
21]. Given the well- established relationship between body 
mass index (BMI) and female hormones, we also analyzed 
the association between BMI with HNCs [22, 23]. In 
most studies (both Milan studies, Aviano, Italy Multicenter, 
Switzerland, and US Multicenter) BMI was ascertained 
at enrollment, while in others (Buffalo, Iowa, Rome, and 
both Japan studies) BMI was ascertained 2–5 years earlier. 
The Pearson correlations were over 0.88, and BMI odds 
ratios (ORs) for HNC were similar between all studies. 
Alcohol consumption was calculated in standardized 
drinks/day [24].
Statistical analyses
Associations between hormone factors and HNC were 
assessed by OR and corresponding 95% confidence intervals 
(CIs) using multivariate logistic regression models. To 
determine summary associations, study- specific estimates 
were included in a multivariate two- stage random- effects 
logistic regression model [25], allowing for study hetero-
geneity. Variables with the largest number of data by 
study are displayed using both random- effects models. 
Pooled odds ratios were also estimated with a fixed- effects 
logistic regression model for each hormone variable, adjust-
ing for age, education, study, BMI, tobacco smoking, and 
alcohol, as described previously [3, 26, 27].
For stratified analyses, separate multivariable models 
were run for never and former/current smokers to mini-
mize the possible confounding of former smokers. The 
same method was applied to alcohol drinking. BMI cat-
egories were separated as: underweight- <18.5 kg/m2, 
normal- 18.5–24.9 kg/m2, overweight- 25–29.9 kg/m2, and 
obese- ≥30 kg/m2. We also included interaction terms to 
determine modifying effects between hormone variables 
and smoking and drinking. A Student’s t- test was used 
to determine whether means for months of exogenous 
hormone differed between cases and controls. All analyses 
were performed using Stata version 14.0 (StataCorp., 
College Station, Texas) and P < 0.05 was considered 
significant.
Results
The distributions of cases and controls by selected char-
acteristics are reported in Table S2. A total of 546 HNC 
cases (36.6%) were nondrinkers versus 1882 (47.2%) 
controls who were nondrinkers. Nonsmokers included 
506 (33.5%) cases and 2536 (63.7%) controls. A high 
school education or more was inversely associated with 
HNCs (OR = 0.77; 95% CI: 0.65–0.92) with a dose–
response effect (Ptrend based on five categories<0.001). This 
association remained after adjustment for hormonal fac-
tors; effect modification with hormone variables was 
P = 0.76. Mean BMI for cases was 23.1 kg/m2 ± 0.12 
standard deviation (SD) versus controls 24.5 kg/m2 ± 0.13 
SD; P < 0.001. No association was observed for HNCs 
by BMI category (Table S3); effect modification for BMI 
with all hormone variables were all P > 0.05; data not 
shown.
Exogenous hormone use
Inverse associations were observed across all HNC and 
cancer sites for both HRT and OC use (Table 1). Respective 
ORs and 95% CIs between ever using HRT and HNC, 
oral cavity cancer, and oropharyngeal cancer were 0.58 
(0.34–0.77), 0.56 (0.32–0.97), and 0.49 (0.31–0.77), respec-
tively. For OC use, a dose–response relationship with age 
was observed, with inverse associations for those who 
started at 31+ years old (OR = 0.37, 95% CI: 0.22–0.63; 
Ptrend < 0.001). When age at first OC use was treated as 
a continuous variable, a similar inverse association was 
observed: OR = 0.61; 95% CI: 0.47–0.82 for all HNCs 
and oropharyngeal cancer (OR = 0.60; 95% CI: 0.39–0.92), 
but not oral cavity cancer (OR = 0.67; 95% CI: 
0.42–1.07).
Among women who used HRT, an inverse association 
with HNC was OR = 0.59 (95% CI: 0.39–0.90) for each 
additional 10 years of age at which HRT was started. For 
every additional 3 years that HRT use continued, HNC 
risk decreased by 13% (OR = 0.87; 95% CI: 0.76–0.99). 
Only seven cases and 26 controls had ever used both 
HRT and OC. There was no significant difference between 
months of HRT use (25.6 ± 60.3 SD vs. 23.5 ± 63.6 SD; 
P = 0.61) or months of OC use (10.4 ± 32.5 SD vs. 
8.2 ± 28.5 SD; P = 0.16) between cases and controls, 
respectively.
Endogenous hormones: reproductive and 
menstrual variables
Giving birth was inversely associated with all HNCs. An 
inverse relationship was observed for age at first pregnancy 
and age at first birth <35 years versus never having been 
pregnant or given birth for all HNCs, oral cancers, and 
oropharyngeal cancers. The number of births was not 
significantly associated with HNCs [Respective ORs and 
95% CIs for HNC: 0.94 (0.88–1.01), oral cavity: 0.93 
(0.83–1.04), and pharynx: 0.92 (0.83–1.02)] (data not 
shown). There were no appreciable associations between 
having had a miscarriage or abortion with HNCs, or with 
subsites (data not shown).
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Menopause at <52 years old was associated with higher 
risk of all HNCs. Menopause due to both natural and 
surgical causes was associated with higher risk of HNCs 
compared to pre- and peri- menopausal women. However, 
when menopause type was adjusted for HRT use, associa-
tions attenuated for both naturally and surgically induced 
menopause [(Natural menopause: OR = 1.46; 95% CI: 
0.74–2.85; n = 98 HRT use/n = 145 no HRT use) and 
Surgical menopause: OR = 1.17; 95% CI: 0.58–2.37; 
(n = 25 HRT use/n = 45 no HRT use)]. No association 
was observed between age at menarche with all HNCs 
or subsites, both in continuous scale (data not shown) 
and categorical scale (<14 vs. 14+ years of age). Similarly, 
menstrual cycle duration (OR = 1.04; 95% CI: 0.94–1.14) 
and menstrual period duration (OR = 0.96; 95% CI: 
0.87–1.05) were not associated with HNCs (data not 
shown).
Between- study heterogeneity was not detected. Inverse 
associations were observed between ever using HRT and 
all HNCs (Fig. 1) as well as oral cavity and oropharyngeal 
cancers in random- effects models [Respective pooled ORs 
and 95% CIs: 0.58 (0.31–0.84); 0.49 (0.29–0.75)]. Similar 
to fixed- effects models, ever OC use was inversely associ-
ated with overall HNCs [Respective pooled ORs and 95% 
CIs: 0.55 (0.28–0.83)] but not for oropharyngeal cancers: 
0.46 (0.06–0.98). Ever giving birth was inversely associated 
with all HNCs as well as both oral cavity and oropharynx 
cancer subsites [Respective pooled ORs and 95% CIs: 0.54 
(0.34–0.75); 0.25 (0.10–0.41); 0.54 (0.21–0.82)].
HNC risk and hormones, by smoking and 
drinking
HRT use
Ever using HRT remained inversely associated with all 
HNCs, oral cavity, and oropharyngeal cancers in ever- 
smokers only (Table 2). An interaction between smoking 
status and HRT was observed for oropharyngeal cancer. 
Interactions for HRT and alcohol drinking were observed 
for HNCs and oral cavity cancers (Pinteraction = 0.01 and 
0.002, respectively).
OC use
The association between oropharyngeal cancer and ever 
OC use was inversely associated for ever- smokers, but 
not observed for never- smokers. No interaction between 
smoking and OC use was observed for HNC overall. 
However, an inverse association was observed between 
OC use and all HNCs in stratified analyses for ever- 
drinkers, with significant interaction (Pinteraction=0.02), but 
not for never- drinkers.
Ever given birth
No interactions were observed between giving birth and 
HNCs when stratified for alcohol drinking. An interaction 
was observed for HNCs and smoking (Pinteraction  = 0.02). 
The risk of oropharyngeal cancer was lower for 
Figure 1. Association between the use of HRT, oral contraceptives, and ever given birth with the risk of head and neck cancer by study in INHANCE 
Consortium.
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ever- smokers who had given birth than for never- smokers. 
Interactions between hormone variables and BMI for HNC 
risk were: P = 0.15 for HRT use, P = 0.50 for OC use, 
and P = 0.78 for ever given birth.
Discussion
This study accomplished an adequately powered investiga-
tion of major exogenous and endogenous hormone- related 
variables on female total HNCs as well as oral cavity 
cancers, and oropharyngeal cancer subsite risk by pooling 
primary data from multiple studies. We confirmed an 
inverse relationship between multiple estrogen- 
progesterone hormone factors and HNC risk among 
females, an understudied population. Associations were 
favorable for high- estrogen endogenous states, specifically 
earlier first pregnancy and earlier menarche, and incon-
sistent for age at menopause which supports risk suscep-
tibility at younger age of exposure. The relationship between 
hormones factors and HNCs appears to be modified by 
alcohol drinking and smoking status, consistent with known 
biological mechanisms of these cancer risk factors on 
female hormones. Considering our stratification for tobacco 
and alcohol exposure still resulted in inverse associations 
Table 2. Risk of head and neck cancer overall and for subsites in tobacco smokers and alcohol drinkers within strata of endogenous and exogenous 
hormones variables, INHANCE Consortium.
Overall head and neck Oral cavity Oropharynx
Cases 
(E/E
–
)
Controls 
(E/E
–
)
OR (95% CI) Pinteract Cases 
(E/E
–
)
Controls 
(E/E
–
)
OR (95% CI) Pinteract Cases 
(E/E
–
)
Controls 
(E/E
–
)
OR (95% CI) Pinteract
Ever used HRT (ever vs. never)
Alcohol drinking status 0.01 0.002 0.75
Never 133/191 415/638 0.50 
(0.25–1.00)
44/95 415/638 0.44 
(0.15–1.26)
10/45 415/638 0.47 
(0.15–1.48)
Ever 219/427 330/685 0.61 
(0.36–1.05)
92/167 330/685 0.70 
(0.36–1.37)
42/127 330/685 0.48 
(0.29–0.80)
Tobacco smoking status 0.06 0.31 0.02
Never 98/199 492/864 0.49 
(0.23–1.04)
41/104 492/864 1.04 
(0.63–1.73)
11/37 492/864 0.70 
(0.25–2.02)
Ever 267/426 283/479 0.50 
(0.31–0.82)
97/161 283/479 0.58 
(0.39–0.85)
41/137 283/479 0.45 
(0.27–0.75)
Ever used OC (ever vs. never)
Alcohol drinking status 0.02 0.61 0.14
Never 21/75 97/532 0.74 
(0.34–1.61)
6/30 97/532 0.53 
(0.15–1.90)
4/20 97/532 0.35 
(0.07–1.88)
Ever 63/273 226/798 0.53 
(0.34–0.83)
23/76 226/798 0.65 
(0.32–1.32)
18/98 226/798 0.54 
(0.26–1.10)
Tobacco smoking status 0.21 0.60 0.01
Never 24/98 184/991 0.82 
(0.46–1.47)
8/41 184/991 0.56 
(0.22–1.45)
8/21 184/991 1.20 
(0.43–3.38)
Ever 63/249 147/378 0.63 
(0.39–1.01)
23/68 147/378 0.83 
(0.37–1.82)
13/62 147/378 0.39 
(0.17–0.91)
Ever given birth (ever vs. never)
Alcohol drinking status 0.28 0.45 0.08
Never 103/41 565/160 0.89 
(0.61–1.30)
42/15 565/160 0.79 
(0.44–1.40)
22/9 565/160 0.85 
(0.29–2.50)
Ever 287/117 990/191 0.50 
(0.29–0.84)
92/45 990/191 0.78 
(0.35–1.72)
67/33 990/191 0.68 
(0.36–1.25)
Tobacco smoking status <0.001 0.12 0.06
Never 104/42 1074/217 0.80 
(0.50–1.27)
42/15 1074/217 0.81 
(0.42–1.56)
30/5 1,074/217 1.39 
(0.46–4.20)
Ever 278/111 520/139 0.68 
(0.46–1.00)
89/43 520/139 0.77 
(0.42–1.43)
59/39 520/139 0.46 
(0.25–0.88)
Models adjusted for study (and center for multicenter studies), age (<40, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75+ years), education 
level (≤high school, > high school), amount of alcohol drinking (nondrinker, 0.1–0.9, 1.0–2.9, 3.0–4.9, and 5.0+ drinks/day), body mass index (normal 
weight, underweight, overweight, and obese), and cumulative tobacco smoking (never smoker, smoked 0–10.0, 10.1–20.0, 20.1–30.0, 30.1–40.0, 
40.1–50.0, 50.0+ pack- years).
E, exposed; E
–
, unexposed; HRT, hormone replacement therapy; OC, oral contraceptives; OR, Odds ratios.
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for hormone variables among those with high cancer risk, 
we interpret this to mean that the decrease in female 
HNC risk could not be solely explained by tobacco or 
alcohol alone.
Some studies on female HNCs suggested a favorable 
effect of some hormone factors [28], while others found 
null associations [28]. Accumulated, the evidence supports 
a mixed causal effect of both sex (biological) and gender 
(psycho- sociological) differences on HNC [29, 30] with 
a protective relationship with younger exposure age.
Biologically higher natural estrogen levels among women 
have been proposed as an explanation for lower risk of 
HNCs compared to men. As ~90% of HNCs are squa-
mous cell carcinomas, this hypothesis is analogous with 
findings among other upper- thoracic squamous cell car-
cinomas in women demonstrating a favorable associations 
of female combination hormones for cancers of the oral 
cavity and pharynx [3], and esophagus [31], including a 
prospective study [32].Associations for hormone use with 
esophageal squamous cell carcinoma were stronger than 
for adenocarcinoma [31, 32]. For HNCs specifically, experi-
mental in vitro and in vivo studies support a plausible 
biological mechanism for hormone ligand action. Lukits 
and colleagues [6] demonstrated evidence for estrogen 
and progesterone receptors in 67 of human HNC surgical 
samples. Colella et al.[33] found that hormone expression 
patterns differ between malignant versus nonmalignant 
oral mucosa tissue. The beta estrogen receptor (ERβ) in 
particular, functions as a tumor suppressor by inhibiting 
proliferation and driving cellular differentiation [34] and 
ERβ positivity has been correlated with improved survival 
of oropharyngeal cancer patients [8]. Moreover, the selec-
tive estrogen receptor modulator, tamoxifen, has been 
shown to arrest G1 in HNC cell lines, sensitizing cancer 
cells to chemotherapy- induced apoptosis [35, 36]. These 
findings indicate that specific biological mechanisms exist 
by which hormone levels can influence HNC phenotypes 
when receptors are activated.
A second explanation for the inverse relationship between 
estrogenic hormones on female HNCs is the influence of 
estrogen on liver metabolism. CYP1B1, part of the 
Cytochrome P450 enzyme superfamily, plays a key role 
in sex hormone metabolism and homeostasis. Shatalova 
et al.[37] found estrogen exposure of premalignant HNC 
cells reduced CYP1B1 gene expression. Yoo et al. [38] 
examined estrogen metabolites in 50:50 HNC case–controls 
and found higher abnormal estrogen metabolism expres-
sion among cases (OR = 15.6;95% CI: 1.1–212.5). The 
stratified hormone analyses for our study showed a stronger 
inverse relationship among ever- drinkers. Given that con-
sistent alcohol drinkers have altered liver metabolism and 
higher estrogen levels, it is plausible that the combination 
of exogenous estrogen level exposure and alcohol may 
work in tandem to decrease HNC risk estimates and may 
explain P values < 0.05 for interaction as well as an 
inverse association for female ever- drinkers (OR = 
0.53[95% CI: 0.34–0.83]. This pattern was confirmed for 
our study when we restricted analyses to heavy drinkers 
(≥3.0 drinks per day) (OR for HRT use = 0.34; 95% CI: 
0.02–6.61 and OR for OC use = 0.36;95% CI: 0.12–1.13). 
Although these CIs include 1, an inverse pattern is preva-
lent for heavy drinkers with a greater inverse association 
than among ever- drinkers. It must also be noted that 
these analyses were restricted to 169 and HNC cases and 
222 controls due to the low prevalence of female heavy 
drinkers.
Considering that women have considerably lower alcohol 
consumption and tobacco use than men (psycho- 
sociological gender- related differences), it is not surprising 
that female HNC incidence is also lower. Modification 
of tobacco smoking/alcohol drinking by female hormones 
on HNC that were observed in our study may partly 
explain the lower HNC incidence rate among women in 
the general population. This would explain psycho- 
sociological factors associated with fewer female HNCs.
Tobacco smoking interacts with female hormones, 
increasing hepatic metabolism and estrogen catabolism 
[39–41]. Increased estrogenic bioavailability augments the 
risk of estrogenic side effects such as deep vein thrombosis 
and female patients who are smokers are routinely cau-
tioned against OC use. Partly due to this medical con-
traindication, there were too few individuals who both 
used OC and smoked in our study to power an accurate 
association estimate.
Although stratified analyses by BMI were hindered by 
low numbers for most BMI categories, the patterns of a 
J- shaped association curve for BMI with HNC are con-
sistent with hormonally associated risk changes found in 
studies for other cancers [42–44].The dose–response 
decrease in HNC risk with longer HRT use duration offers 
further evidence for a real relationship. Furthermore, earlier 
age at pregnancy and/or birth were also favorably associ-
ated with HNC risk than never being pregnant or having 
given birth. This also supports the notion that there is 
a specific age range of hormone exposure that benefits 
women at younger reproductive age, similar to observa-
tions found for breast cancer [6, 45].
Due to the predominant role of HPV, causing approxi-
mately 70% of oropharyngeal cancers [15], oropharyngeal 
cancer must be uniquely considered in light of female 
hormones. At any given time, approximately 4–7% of 
individuals are expected to have oral or oropharyngeal 
HPV infection [46, 47]. In half of these individuals, these 
infections are cleared by the immune system [48]. It is 
already been observed that men are more likely to have 
an HPV infection than women and that sexual behavior 
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differences could only explain 16% of this prevalence dif-
ference [46]. Women also have a higher preponderance 
for autoimmune diseases such as Hashimoto thyroiditis 
and multiple sclerosis than men and have a stronger 
allograph rejection response than men, indicating that 
certain diseases are indeed mediated by female sex hor-
mones [49, 50]. This is supported by the observation that 
sex hormones have direct effects mediated via hormone 
receptors in immune cells, act through their actions on 
epithelial cells and stromal fibroblast secretion of growth 
factors [51], and has been observed to alter epithelial cell 
proliferation in the female reproductive tract [50]. In an 
epidemiological study among postmenopausal women, who 
have lower physiological estrogen states, reduced immu-
nologic fitness was observed to account for 12% of HPV 
infections [52]. However, the mechanism for how the 
stronger immune response conferred by female sex hor-
mones affects oropharyngeal cancers in response to HPV 
infection has not been examined, to the best of our 
knowledge, and warrants further study.
As with all case–control studies, recall bias is a limita-
tion. However, we used incident cases, which is distinct 
from cases identified before data on risk factors were 
collected, making recall bias less likely. Many study centers 
were hospital- based, leading to selection bias suspicion 
of controls with hormone use- related conditions. However, 
the majority of hospital controls were unhealthy, hospital-
ized due to other illnesses unrelated to hormone use, 
rather than cancers. Another limitation of hospital- based 
studies is lack of external validity, whereby the hospital 
population differs from the general population. However, 
the fact that we also found inverse associations for hor-
mone variables with HNCs across the population- based 
studies of Iowa, Milan (2006–2009), and US multicenter 
contradicts the possibility of hospital- based selection bias. 
Further, the magnitudes of the inverse associations that 
we have observed in our study are not dissimilar to pre-
vious prospective studies on female HNC and hormone 
factors [53, 54].
Our study is strengthened by a high number of female 
incident HNC cases, enabling us to evaluate the relation-
ships between female hormones and HNC, and relationships 
stratified by tobacco smoking and alcohol drinking. The 
consistency of findings for high- estrogen states among both 
endogenous and exogenous hormone factors supports a 
true inverse association between estrogen and HNC, but 
this association may be stronger at earlier age of exposure 
[55]. The HRT users in our study were taking HRT for 
menopausal symptoms, which consisted of both estrogen 
and progesterone combined rather than unopposed estrogen. 
This warrants further experimental studies to understanding 
the mechanisms behind which female hormones act on 
head and neck cells to prevent or reduce cancer risk.
In conclusion, this study supports a favorable associa-
tion of female hormones with HNC. It also suggests that 
the lower incidence of female HNCs may be due to a 
combination of exogenous and endogenous hormone 
exposure and different smoking and drinking risk 
exposures.
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